1 Pre-conceptional maternal vitamin B12 supplementation improves offspring 2 neurodevelopment at 2 years of age: PRIYA trial 3 Type of manuscript: Brief Research Report 4 5 Naomi D'souza<sup>1†</sup>, Rishikesh V Behere<sup>1†</sup>, Bindu Patni<sup>2</sup>, Madhavi Deshpande<sup>2</sup>, Dattatray Bhat<sup>1</sup>, 6 Aboli Bhalerao<sup>1</sup>, Swapnali Sonawane<sup>1</sup>, Rohan Shah<sup>1</sup>, Rasika Ladkat<sup>1</sup>, Pallavi Yajnik<sup>1</sup>, 7 Kalyanaraman Kumaran<sup>3</sup>, Caroline Fall<sup>3</sup>, Chittaranjan S Yajnik<sup>1\*</sup>. 8 9 10 11 1 - Diabetes Unit, KEM Hospital Research Center, Pune, India 2 - TDH Rehabilitation and Morris Child Development Centre at KEM Hospital, Pune 12 3 - MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United 13 Kingdom 14 15 16 17 † The authors have contributed equally to this work and share first authorship 18 \* Corresponding author 19 Dr Chittaranjan S Yajnik 20 21 Director, Diabetes Unit KEM Hospital Research Center 22 489, Rasta Peth 23 Pune – 411011, India 24 Email: csyajnik@gmail.com 25 Ph: +919822847481 26 27 Number of Pages: 16 28 29 Word count: 3836 Number of Tables: 2 30 Number of figures: 2 31 32 33 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

34

- 35 **Background:** Nutritional interventions during the first 1000 days of life improves lifelong
- 36 health. Better pre-conceptional maternal nutrition improves the nutrition of the early embryo.
- 37 Vitamins B12 and folate are important for fetal neural development. Vitamin B12 deficiency
- is common in India.
- 39 **Methods:** In the Pune Rural Intervention in Young Adolescents (PRIYA) adolescents (N=557,
- 40 226 females) were provided with vitamin B12 (2µg/day) with or without multiple
- 41 micronutrients, or a placebo, from preconception until delivery. All groups received mandatory
- 42 iron and folic acid. We used the Bayley's Scale of Infant Development (BSID-III) at 24-42
- 43 months of age to investigate effects on offspring neurodevelopment. We examined cord blood
- concentrations of brain-derived neurotropic factor (BDNF).
- 45 **Results:** Participants in the three groups had similar baseline B12 levels. These improved in
- 46 the B12 supplemented groups at pre-conceptional and pregnancy (28 weeks gestation)
- 47 measurements, reflected in higher cord holo-TC levels compared to the placebo.
- Neurodevelopmental outcomes are available for 74 children. Offspring in the B12 alone group
- 49 (n=21) performed better than the placebo (n=27) on cognition (p=0.044) and language
- 50 (p=0.020) domains (adjusted for maternal baseline B12 levels). There were no differences
- between the B12+MMN (n=26) and placebo group. Cord blood BDNF levels were highest in
- 52 the B12 alone group (not statistically significant).
- 53 Conclusion: Pre-conceptional vitamin B12 supplementation improved maternal B12 status
- and offspring neurodevelopment at 2 years of age. The usefulness of cord BDNF as a marker
- of brain development needs further investigation. Our results highlight the importance of
- intervening in the pre-conceptional period.
- 57 **Key words:** Vitamin B12, pre-conception, supplementation, neurodevelopmental outcome,
- 58 offspring

59

60

61

62

63

64

65

66

67

68

69

70

71

## 1.0 Introduction

The developing fetus is dependent on its mother for its nutrition. Maternal undernutrition before and during pregnancy affects fetal growth and development, the effects of which may predispose an individual to undesirable outcomes in later life. This concept is called 'fetal programming'. This is the backbone for the Developmental Origins of Health and Disease (DOHaD) paradigm (1,2). Pregnancy and the first two years of life (1000 days) are considered the most crucial window for programming (3).

Maternal nutritional factors (both macro and micronutrients) influence neurodevelopmental processes *in utero*, such as neurogenesis, myelination, synaptogenesis, and cortical brain growth (3). Vitamins B12 and folate are of special interest due to their effects on cellular growth (DNA synthesis, and epigenetic regulation by methylation) mediated by the one carbon metabolism pathway (4). Offspring of mothers with low maternal vitamin B12 and folate during pregnancy have a higher risk of neural tube defects and neurodevelopmental disorders (autism, ADHD), poorer cognitive development and smaller brain volumes in childhood (5–8). In animal models (rats), offspring of mothers exposed to a high folate and low vitamin B12 diet show lower levels of the neurotrophic factor Brain Derived Neurotrophic Factor (BDNF) in the brain, and poorer cognitive function (9,10).

In India, vitamin B12 deficiency is widely prevalent in pregnant women (50-70%) (11,12) and is attributable to the socio-cultural practice of vegetarianism and poor economic status (13–16). This deficiency is associated with a range of adverse pregnancy and offspring health outcomes (17). In prospective birth cohorts (the Pune Maternal Nutrition study and the IAEA B12 study) from western India, we have earlier shown that exposure to low maternal vitamin B12 *in utero* is associated with poorer cognitive functioning at the age of 2 and 9 years in the offspring (18,19). However, public health policy in India mandates only iron and folic acid supplementation to women in the reproductive age group, and during pregnancy and lactation. A randomized controlled trial in South India showed that supplementing 50 μg/day oral B12 from 14 weeks of pregnancy until 6 weeks postpartum improved B12 concentrations in breast milk, the vitamin B12 status of infants at 6 weeks and infant cognitive function at 30 months of age (20,21).

Important milestones in fetal neural development such as neural tube closure are completed by 26-28 days of gestation (22). The majority of pregnancies in India are unplanned, and by the time pregnancy is detected (typically between 10-14 weeks gestation) this early developmental window is lost. Pre-conceptional intervention will ensure that the mother has improved vitamin stores during the early neurodevelopmental period. The success of pre-conceptional folic acid supplementation in preventing neural tube defects is well known (23–25). Few studies have examined the effects of pre-conceptional maternal micronutrient supplementation on offspring neurodevelopment in India. This approach will expand the 1000 days concept to include the pre-conceptional period.

The Pune Rural Intervention in Young Adolescents (PRIYA) is a pre-conceptional vitamin B12 and multi micronutrient supplementation trial in adolescent participants of the Pune Maternal Nutrition Study. We report neurodevelopmental outcomes at 2 years of age in the offspring of female participants of the trial. We hypothesised that pre-conceptional B12 supplementation in the mothers would contribute to better neurodevelopmental outcomes in their offspring.

## 2.0 Material and Methods

120 2.1 PRIYA trial

- The PRIYA trial methods have been previously published (26). Briefly, The Pune Maternal
- Nutrition Study (PMNS) is a pre-conceptional observational birth cohort set up in 1993 (Figure
- 1). Non-pregnant women were recruited from six villages around Pune and those who became
- pregnant were followed through pregnancy. Seven hundred and sixty-two children were born
- and followed up serially. At age ~17 years, 690 participants from the PMNS cohort (11) were
- screened for inclusion in the PRIYA trial. Of these, 133 were excluded due to severe vitamin
- B12 deficiency or systemic illnesses. Five hundred and fifty-seven (266 females) participants
- were randomized (Figure 1) to receive either a placebo, B12  $(2\mu g/day)$  + multiple
- micronutrients (MMN) or B12 alone (2µg/day). The composition of the MMN tablet was
- 130 guided by the WHO/UNICEF/UNU international multiple micronutrient preparation
- (UNIMMAP), excluding folic acid because the mandated IFA tablets (100 mg elemental Iron
- and  $500 \mu g$  folic acid once a week) were given to all participants as per Government of India
- recommendations. Female participants in the trial received supplementation daily until their
- 134 first delivery. They and the study team were blinded to the vitamin/micronutrient
- supplementation.
- Participants were followed up regularly for any health problems, and marriages were recorded.
- Married women were monitored to detect pregnancy which was confirmed by a urine
- pregnancy test. At 28 weeks gestation, mothers visited the Diabetes Unit, KEM Hospital
- 139 Research Center, Pune for evaluation. This included socio demographic information (assessed
- using the Standard of Living Index questionnaire of the NFHS of India), anthropometry,
- physical examination and blood measures of circulating vitamins B12, folate, B2 and B6. At
- birth, delivery details and the baby's size were recorded. Maternal and cord blood samples were
- 143 collected.
- 144 These measurements were conducted in participants at baseline, 6-12 months after the start of
- the intervention (at ~18 years of age), at 28 weeks gestation, and in cord blood. A Hemogram
- was measured on a Beckman Coulter analyzer (Miami, Florida, USA) on the day of the
- 147 collection. Plasma vitamin B12 and folate were measured using a microbiological assay and
- total homocysteine, vitamin B2 and B6 by HPLC as described in the PRIYA trial methods
- publication (26). Plasma BDNF was measured in cord blood using ELISA (XpressBio)
- 150 (Frederick, USA)
- 151 2.2 Neurodevelopmental assessments
- The offspring born in the trial were followed up every 6 months until 2 years of age, for
- measurements of their growth. Once they reached 24 months of age, the parents were
- approached regarding participation in the neuro-cognitive study, and their written informed
- consent was obtained. An appointment was scheduled for the neurodevelopmental assessment
- at the Child Development Center (TDH center), KEM Hospital, Pune. The child and mother
- were transported to the center from their home on the morning of the assessment.
- 158 The neurodevelopmental assessment was performed using the Bayley's Scale of Infant
- Development (BSID-III) (27). The BSID-III assesses the developmental status of infants from
- 160 1 to 42 months of age. The scales assess five domains across three main subscales: 1) cognitive
- which includes items such as attention to familiar and unfamiliar objects, looking for a fallen
- object, and pretend play, 2) language which assesses receptive and expressive language, via
- recognition of objects and people, following directions, and naming objects and pictures, and
- 3) motor which assesses gross and fine motor skills such as grasping, sitting, stacking blocks,

- and climbing. The assessment was performed by trained clinical psychologists certified to
- perform the BSID-III. Testing was carried out in a quiet room, with a parent or guardian
- present, and instructions were provided in a language that was comfortable for the child. All
- 168 children were assessed within a time window of 24 to 42 months of age. Each test protocol was
- independently reviewed and scored by two raters.
- The BSID-III test yields raw scores based on the performance of the child on test items for
- 171 cognitive, expressive, and receptive communication, and fine and gross motor skills. The raw
- scores were converted into age standardized scaled scores as recommended in the manual.
- Summation of the scaled scores yields 3 composite scores for the cognitive, language and motor
- skills domains. We used the composite scores in our analysis. Composite scores were
- categorized into average, below or above average performance, based on standardized criteria
- provided in the manual, where average is 100 with SD of 15 and a score of <85 is considered
- to be below average (27).
- As part of ongoing assessments in the PMNS cohort, maternal IQ was assessed in some of the
- mothers at age 22~24 years using the Weschler's Adult Intelligence Scale-IV (WAIS-IV).
- 180 2.3 Ethical considerations
- Details of community participation in the planning of this trial has been described earlier (26).
- The trial was approved by the KEM Hospital Research Centre Ethics committee (no 1242) and
- monitored by a Data Safety Monitoring Board (DSMB) and a Scientific Advisory Committee
- 184 (SAC). The trial was registered with the CTRI (2012/12/003212) and ISRCTN (32921044).
- Neurodevelopmental assessment of the offspring was also approved by the Institutional ethics
- 186 committee of the KEM Hospital research center and registered in (clinical trials.gov ID:
- 187 NCT03088189).
- 188 2.4 Statistical Analysis
- The purpose of our analysis was to see if pre-conceptional B12 and micronutrient
- 190 supplementation in the mothers led to improvement in offspring neurodevelopmental
- 191 performance (composite BSID-III scores) at 2 years of age. We also investigated the effect of
- intervention on circulating vitamin levels in the mother and cord blood, and on cord blood
- 193 BDNF levels.
- We first examined whether randomization had equally distributed potential confounders such
- as parental education and standard of living index, and maternal age, IQ, and anthropometry,
- across the three intervention groups.
- 197 All data were represented as either mean and standard deviation (for normally distributed
- variables) or median inter-quartile range (IQR, for skewed variables). All right skewed
- variables were log transformed. We used t-tests or ANOVA to test the significance of
- 200 differences in outcomes between the intervention groups, and ANCOVA to test the significance
- of differences in outcomes between the intervention groups after adjusting for maternal B12
- levels at screening. We used the Mann-Whitney U test to the significance of difference in cord
- 203 BDNF values between the intervention groups.

#### 3.0 Results

204

- Of the 266 women randomized in the trial, 182 were married, 166 became pregnant, and 149
- delivered a live baby. Between May 2017 and February 2020, we approached the parents of 85
- 208 children who had attained the age of 2 years of age, for participation in the neurodevelopmental

study. Further assessments after February 2020 had to be halted due to the COVID-19 209 pandemic. None of the children had significant neurodevelopmental disorders (cerebral palsy, 210 seizure disorders, or neural tube defects). Seven children who were above the inclusion age of 211 42 months as per the BSID norms, were excluded from analysis after confirming that they had 212 achieved appropriate neurodevelopment for 42 months of age. Assessment could not be 213 completed in 4 children. Our analysis is based on the remaining 74 children. The median age 214 of the children at the time of performing the BSID was 29 months (Table 1). There were 42 215 boys and 32 girls; of these, 27 were in the placebo group, 26 in the B12+MMN and 21 in the 216 B12 alone group. There were no differences in gestational age at delivery, birth weight, length 217 218 or head circumference amongst the offspring in the three intervention groups. Similarly, there were no differences in parental education, standard of living index, maternal age, or IQ. (Table 219

- The children who were not invited for the study because they were below 24 months of age
- 222 differed from those studied; they had higher socio-economic status and parental education,
- 223 higher maternal and cord B12 and holotranscobalamin (holo-TC) and lower cord homocysteine
- compared to the study group. (Supplementary Table 1).
- 3.1 Effect of supplementation on maternal and newborn micronutrient status, and birth
- 226 measures

1)

- 227 At baseline, maternal B12 and holo-TC levels were similar across the three intervention groups
- 228 (Table 1). Fifty one percent of the females had vitamin B12 deficiency at screening (B12<150
- pM), and this reduced to 22% at 6-12 months after starting intervention. There was a rise in
- vitamin B12 and holo-TC levels in the B12 supplemented groups compared to the placebo
- group, both pre-conceptionally (18 years of age) and at 28 weeks of gestation. Cord blood
- levels of holo-TC were significantly higher in the B12 supplemented groups compared to the
- placebo group, though B12 levels were similar.
- 234 Plasma homocysteine concentrations which were high but similar at baseline in the three
- groups of mothers, fell substantially in the vitamin B12 supplemented groups pre-
- conceptionally. During pregnancy, as expected, plasma homocysteine concentrations fell in all
- groups and were similar in the three groups during pregnancy as well as in cord blood.
- 238 Circulating folate concentrations were similar at baseline in the three groups and increased
- during pregnancy (due to supplementation). Folate levels were significantly lower at 28 weeks
- 240 gestation in the B12+MMN group as compared to the placebo. Folate levels were similar in the
- 241 cord blood across the groups. Circulating vitamin B2 and B6 concentrations increased from
- baseline in the B12 +MMN group before and during pregnancy and in cord blood.
- 243 Hemoglobin concentrations were similar in the mother and the baby across all the groups.
- 3.2 Comparison of BSID scores and cord BDNF between supplementation groups
- 245 Age standardized composite scores in the domains of cognition, motor and language
- development were obtained on 74 children. There was no difference in performance between
- 247 males and females (supplementary Table 3). No significant developmental delays were
- observed in any of the children (score < 69). Few children showed a below average
- performance on the cognitive (4.0%, n=3), motor (4.0%, n=3), and language domain (8.1%,
- 250 n=6) (score < 85) (supplementary table 2).
- 251 The offspring of mothers in the B12 alone group performed the best in the cognitive and
- language domains, and significantly better than the placebo group (Table 2). This difference
- 253 persisted after adjusting for the baseline plasma vitamin B12 concentrations, the latter were not

- related to neurodevelopmental outcomes. There was a 5 -7% increase in cognition and language 254
- composite scores in the B12 alone group over the placebo group. 255
- There were no significant differences between the B12+MMN group and the placebo group on 256
- any of the neurodevelopmental subscales. 257
- The two intervention groups had higher cord BDNF values than the placebo group, the B12 258
- alone group had the highest values, however the difference was non-significant (Table 1). Cord 259
- blood BDNF values did not show significant associations with any of the BSID-III composite 260
- 261 scores.

262

263

## 4.0 Discussion

- In this rural Indian population with a substantial prevalence of B12 deficiency, we found that 264
- supplementation of adolescents with 2 µg /day of B12 significantly improved their own B12 265
- status (total B12 and holo-TC) and cord blood holo-TC. Offspring whose mothers received 266
- vitamin B12 alone performed better than offspring of mothers in the placebo group in 267
- neurodevelopmental assessments (cognitive and language domain of the BSID-III test at 24-268
- 42 months of age). Offspring whose mothers received B12+MMN performed similarly to the 269
- placebo group. 270
- The role of pre-conceptional folic acid supplementation in preventing NTDs is well established, 271
- especially in western (mainly non-vegetarian) populations (23,24). In vegetarian populations 272
- like India, vitamin B12 is likely to play a similar role, probably because both folate and B12 273
- act as cofactors for the enzyme methionine synthase, in methylation reactions. Studies in India 274
- have highlighted an association of both maternal vitamin B12 and folate with different 275
- outcomes in the offspring including neurodevelopmental performance. Studies in Pune showed 276
- an association of low maternal vitamin B12 status (low holo-TC concentrations and TCN2 277 polymorphisms) with risk of NTD, and a positive association between maternal vitamin B12
- 278
- status during pregnancy and offspring neurocognitive performance at 2 and 9 years of age 279
- (5,18,19). A study in North Indian children aged 12–18 months found that both vitamin B12 280
- and folate status had significant associations with cognitive performance (28) while a study in 281
- Mysore found that higher maternal folate concentrations, but not vitamin B12, during 282
- pregnancy were associated with better cognitive ability in children at 9-10 years of age (29). 283
- Adequate status of both vitamins is likely to be important for brain development and function. 284
- Recent systematic reviews, including both observational and interventional studies, support a 285
- moderate level of evidence for a role of maternal B12 status in determining offspring cognitive 286
- function, and highlight a need for more studies from developing countries (17,30). Studies in 287
- Mexico and Singapore have also reported an association between maternal dietary intake of 288
- vitamin B12 and offspring cognitive abilities (31,32). Observations in the ALSPAC cohort in 289
- the UK suggests a weak association of maternal a genetic determinant of circulating vitamin 290
- 291 B12 concentrations (FUT2) and offspring IQ at 8 years of age (33). On the other hand, a cohort
- study in Canada, showed no significant associations between maternal vitamin B12 292
- concentrations and BSID-III outcomes in their offspring at 18 months (32). This may be due 293
- to a lack of significant variation in maternal vitamin B12 status, given the low prevalence of 294
- 295 vitamin B12 deficiency in their population (34).
- Our findings from this pre-conceptional maternal micronutrient supplementation trial fills an 296
- important gap in the literature. Our observations are supported by a maternal B12 297
- supplementation study from south India, which supplemented mothers with 50 µg vitamin B12 298
- from the 1st trimester of pregnancy until 6 weeks postpartum. Supplementation improved 299

maternal B12 levels in the third trimester (20) and offspring showed a better neurodevelopmental outcome (language domain) at 30 months of age (21). Vitamin B12 (1.8 μg) and/or folic acid (150 μg) supplementation in 6–30-month-old children for a period of 6 months showed improvement in their neurocognitive performance. The B12 alone group showed improvement in gross motor functioning and the B12 + folic acid group in gross motor as well as problem-solving functioning compared to the placebo; folic acid alone had no effect (35).

The wide prevalence of B12 deficiency is unique to the Indian context due to the socio-cultural practice of vegetarianism. Severe absorption defects (i.e. pernicious anaemia) are rare and vitamin B12 deficiency is largely a low dietary intake problem (15–18). This offers a unique opportunity to control a modifiable risk factor at the public health scale to improve neurodevelopment and human capital in the next generation. Our choice of a nearrecommended dietary allowance (RDA) dose of B12 (2 µg/day) was based on our earlier studies showing adequate absorption of oral B-12 (36) in this population and the demonstration in a pilot study of improvement in B-12 and homocysteine status after oral supplementation for 1 year (37). In another study of severely B12 deficient girls, (plasma B12 <100 pmol/l) we demonstrated an improvement in haematological parameters and peripheral and autonomic nerve functions after supplementing 2 µg/day of vitamin B12 for 11 months (38). Thus, we believe that our current study fills an important gap to help public health policy to supplement a physiological dose of vitamin B12 to adolescents and reproductive age women to improve not only their own health but also that of the next generation. Being aware of the difficulties of achieving long term compliance with tablet supplementation in relatively asymptomatic individuals, we have recently reported the efficacy of commonly eaten vitamin fortified food items (nutrient bar and yogurt) to achieve better vitamin B12 status (39). All these approaches are usable in the national programmes to improve micronutrient nutrition of children, adolescents and pregnant mothers.

The improved cognitive outcomes were seen specifically in the B12 alone supplemented group and not in the B12+MMN group. TheB12 alone group achieved higher cord B12, holo-TC and BDNF levels compared to the B12+MMN group, despite a similar daily dose of B12. Though we are unsure about the reason for this difference, the possibilities include differences in compliance and absorption. Evidence for the effects of maternal multiple micronutrient supplementation on offspring outcomes is inconsistent. A systematic review from 9 trials (6 of which used UNIMAP micronutrient composition) did not find favourable effects on child mortality, birth size, or offspring cognition (40).

Vitamins B12 and folate participate in the one-carbon metabolism pathway to 1) stimulate synthesis of precursor nucleotides for DNA synthesis, and 2) generate the universal methyl donor S-Adenosyl methionine (SAM) which is involved in methylation of DNA (an important epigenetic mechanism), proteins and lipids and generating neurotransmitters(41,42). These mechanisms are reputedly involved in fetal growth and differentiation and a deficiency or imbalance of these may result in permanent change in the structure and function of developing tissues which may manifest as disorders in later life ('fetal programming') (1). We have demonstrated alterations in adiposity and insulin resistance in children whose mothers had an imbalance of these vitamins (low B12 – high folate) during pregnancy (11). Animal studies have shown differences in the expression of neurotrophic factors such as BDNF in the brains of fetuses whose mothers were exposed to low vitamin B12 status (9). In our study, though we did not find significant differences in cord blood BDNF concentrations between intervention groups, the values tended to be higher in the B12 alone group. Further studies are required to understand the utility of cord BDNF levels as a neurodevelopmental marker in human beings.

Neurodevelopment is a dynamic process that involves neurogenesis, neuronal migration, cortical growth and gyrification, starting in early pregnancy and lasting until infancy (first 1000 days). The pre- and periconceptional period is an important window within this broader window because of 'epigenetic reprogramming' of the conceptus which happens within 48-72 hours of conception(43). The majority of pregnancies are unplanned, and women approach the healthcare system after this window. Our intervention was specifically started in adolescence to ensure adequate micronutrient stores in the mother from before conception, in time to support gametogenesis, conception, embryogenesis, organogenesis, and placentation. (42,44). The success of pre-conceptional folic acid supplementation in preventing NTDs is well known (23–25). Thus, we propose that the 1000-day window should be expanded to include the preconception period. This would shift the action from the clinic to the community and will fit well into a multitude of adolescent and reproductive age programs across the world.

Additional strengths of our study include a trial within a cohort in which original observations were made, the RCT design which ensured that potential confounders were similarly distributed between allocation groups. For example, home environmental factors that can influence child neurodevelopment - parental education, maternal IQ and socio-economic status- were similar across intervention groups. High rates of participation in the trial, high rates of follow up, and of sample collection at delivery are also noteworthy. Exclusion of women with severe B12 deficiency (<100pM) from a placebo-controlled trial on ethical grounds reduced the power of the study because they and their offspring could have benefited the most with B12 intervention. The COVID pandemic also interfered with our ability to test more children for neurodevelopment and meant that we missed the children of women who became pregnant later and at older ages. Despite these limitations we were able to see the beneficial effects of the intervention. We expect that the performance on the Bayley's scale, will reflect in neurodevelopment indices at a later age. This will be tested in subsequent follow ups.

## 5.0 Summary and Conclusion

We found that pre-conceptional maternal supplementation with a near RDA dose ( $2 \mu g/day$ ) of vitamin B12 exposed their offspring to higher vitamin B12 status peri-conceptionally and during pregnancy. This was associated with better neurodevelopmental performance in the children, in cognitive and language domains, between 24-42 months of age. Our study highlights an important role for maternal vitamin B12 on offspring neurodevelopment. We urge that the first 1000 days window be extended to include the pre-conceptional period. Our findings have strong implications for public health policy to improve vitamin B12 status of young adolescents and reproductive age women in populations with a sizable vitamin B12 deficiency. We foresee benefits of such a policy to many national nutrition programmes in India.

# Figure 1 Consort depicting the recruitment of study participants

Figure 2 Bar graph showing comparison between placebo and treatment groups on BSID-III domains

#### **Authors contributor statement**

CSY and RVB designed the neurocognitive follow-up study. ND and RVB analysed the data and wrote the first draft. BP and MD performed and reported the neurocognitive assessments. DB performed the biochemical measurements. AB contributed to the statistical analysis. SS and RS conducted the follow-up of the participants. KK, RL, and PY contributed to conducting the PRIYA trial. CSY and CF designed the original PRIYA trial. CSY and CF edited the final manuscript. All authors contributed to the article and approved the submitted version.

## **Conflicts of Interest**

The authors declare that they have no conflicts of interest.

# Acknowledgments

We are grateful to the participants of the PMNS for their cooperation in this trial. We acknowledge the contribution of the field workers - Mr Ankush Bhalerao, Mr Suresh Chougule, Mr Vishnu Solat and Ms Rajani Bendge, Ms Malti Raut, Ms Mangal Gaikwad, Ms Sujata Jagtap, Ms Sarla Bagate, Ms Jayshri Kalokhe in conducting the trial. We thank Ms Anagha Deshmukh, Ms Sarah Khan, Ms Deepa Raut, Ms Sayali Wadke, Ms Rajashree Kamat for their assistance in data collection.

## **Funding**

- The PRIYA trial is funded by the Indian Council of Medical Research (58/1/8/
- 414 MRC-ICMR/2009/NCD-II) and Medical Research Council, UK (MR/J000094/1) as
- part of an Indo-UK collaborative call.
- The biological sample collection and analysis was funded by the DBT-CEIB grant
- 417 BT/PR12629/MED/97/364/2016
- 418 The neurocognitive follow up and cord BDNF measurements was supported by the
- DBT/Wellcome India Alliance Fellowship [IA/CPHI/161502665] awarded to RB.
- 420 CSY was visiting professor at Danish Diabetes Academy & Southern University of Denmark
- 421 (2016-2018) which was funded by NOVO-NORDISK FONDEN.

## References

- 1. Lucas A. Programming by early nutrition in man. Ciba Found Symp. 1991;156:38–50;
- discussion 50-55.
- 2. Barker DJP. The origins of the developmental origins theory. J Intern Med. 2007
- 444 May;261(5):412–7.
- 3. Cusick SE, Georgieff MK. The Role of Nutrition in Brain Development: The Golden
- Opportunity of the "First 1000 Days." J Pediatr. 2016 Aug;175:16–21.
- 4. Kalhan SC. One carbon metabolism in pregnancy: Impact on maternal, fetal and neonatal
- 448 health. Mol Cell Endocrinol. 2016 Nov;435:48–60.
- 5. Godbole K, Gayathri P, Ghule S, Sasirekha BV, Kanitkar-Damle A, Memane N, et al.
- 450 Maternal one-carbon metabolism, MTHFR and TCN2 genotypes and neural tube defects
- in India. Birt Defects Res A Clin Mol Teratol. 2011 Sep;91(9):848–56.
- 452 6. Suren P, Roth C, Bresnahan M, Haugen M, Hornig M, Hirtz D, et al. Association
- between maternal use of folic acid supplements and risk of autism spectrum disorders in
- 454 children. JAMA. 2013;309–6.
- 455 7. Ars CL, Nijs IM, Marroun HE, Muetzel R, Schmidt M, Steenweg-de Graaff J, et al.
- 456 Prenatal folate, homocysteine and vitamin B12 levels and child brain volumes, cognitive
- development and psychological functioning: the Generation R Study. Br J Nutr. 2016 Jan
- 458 22;1–9.
- 8. Schlotz W, Phillips DI. Fetal origins of mental health: evidence and mechanisms. Brain
- 460 Behav Immun. 2009;23(7):905–16.
- 9. Sable P, Dangat K, Kale A, Joshi S. Altered brain neurotrophins at birth: consequence of
- imbalance in maternal folic acid and vitamin B12 metabolism. Neuroscience. 2011
- 463 Sep;190:127–34.
- 10. Sable PS, Kale AA, Joshi SR. Prenatal omega 3 fatty acid supplementation to a
- micronutrient imbalanced diet protects brain neurotrophins in both the cortex and
- hippocampus in the adult rat offspring. Metabolism. 2013 Nov;62(11):1607–22.
- 11. Yajnik CS, Deshpande SS, Jackson AA, Refsum H, Rao S, Fisher DJ, et al. Vitamin B12
- and folate concentrations during pregnancy and insulin resistance in the offspring: the
- Pune Maternal Nutrition Study. Diabetologia. 2007 Nov 29:51(1):29–38.
- 12. Finkelstein JL, Kurpad AV, Thomas T, Srinivasan K, Duggan C. Vitamin B12 status in
- pregnant women and their infants in South India. Eur J Clin Nutr. 2017;71(9):1046–53.
- 13. Chanarin I, O'Hea A-M, Malkowska V, Rinsler MG, Price AB. MEGALOBLASTIC
- 473 ANAEMIA IN A VEGETARIAN HINDU COMMUNITY. The Lancet. 1985
- 474 Nov;326(8465):1168–72.
- 475 14. Price SR. Observations on dietary practices in India. Hum Nutr Appl Nutr. 1984
- 476 Oct;38(5):383–9.

- 15. Jathar VS, Inamdar-Deshmukh AB, Rege DV, Satoskar RS. Vitamin B<sub>12</sub> and Vegetarianism in India. Acta Haematol. 1975;53(2):90–7.
- 16. Yajnik CS, Deshpande SS, Lubree HG, Naik SS, Bhat DS, Uradey BS, et al. Vitamin
- 480 B12 deficiency and hyperhomocysteinemia in rural and urban Indians. J Assoc
- 481 Physicians India. 2006 Oct;54:775–82.
- 482 17. Behere RV, Deshmukh AS, Otiv S, Gupte MD, Yajnik CS. Maternal Vitamin B12 Status
- During Pregnancy and Its Association With Outcomes of Pregnancy and Health of the
- Offspring: A Systematic Review and Implications for Policy in India. Front Endocrinol.
- 485 2021 Apr 12;12:619176.
- 18. Bhate V, Deshpande S, Bhat D, Joshi N, Ladkat R, Watve S, et al. Vitamin B 12 Status of
- Pregnant Indian Women and Cognitive Function in their 9-year-old Children. Food Nutr
- 488 Bull. 2008 Dec;29(4):249–54.
- 19. Bhate VK, Joshi SM, Ladkat RS, Deshmukh US, Lubree HG, Katre PA, et al. Vitamin
- B12 and folate during pregnancy and offspring motor, mental and social development at
- 491 2 years of age. J Dev Orig Health Dis. 2012 Apr;3(2):123–30.
- 492 20. Duggan C, Srinivasan K, Thomas T, Samuel T, Rajendran R, Muthayya S, et al. Vitamin
- 493 B-12 Supplementation during Pregnancy and Early Lactation Increases Maternal, Breast
- Milk, and Infant Measures of Vitamin B-12 Status. J Nutr. 2014 May 1;144(5):758–64.
- 495 21. Thomas S, Thomas T, Bosch RJ, Ramthal A, Bellinger DC, Kurpad AV, et al. Effect of
- Maternal Vitamin B12 Supplementation on Cognitive Outcomes in South Indian
- 497 Children: A Randomized Controlled Clinical Trial. Matern Child Health J. 2019
- 498 Feb;23(2):155–63.
- 22. Greene NDE, Copp AJ. Neural Tube Defects. Annu Rev Neurosci. 2014 Jul 8;37(1):221–
- 500 42.
- 23. Wald N, Sneddon J, Densem J, Frost C, Stone R. Prevention of neural tube defects:
- results of the Medical Research Council Vitamin Study. Lancet. 1991;338(8760):131–7.
- 503 24. Czeizel AE, Dobó M, Vargha P. Hungarian cohort-controlled trial of periconceptional
- multivitamin supplementation shows a reduction in certain congenital abnormalities. Birt
- Defects Res A Clin Mol Teratol. 2004 Nov;70(11):853–61.
- 506 25. Central Technical Co-ordinating Unit, ICMRCentral Technical Co-ordinating Unit,
- 507 ICMR. Multicentric study of efficacy of periconceptional folic acid containing vitamin
- supplementation in prevention of open neural tube defects from India. Indian J Med Res.
- 509 2000 Dec;112:206–11.
- 510 26. Kumaran K, Yajnik P, Lubree H, Joglekar C, Bhat D, Katre P, et al. The Pune Rural
- Intervention in Young Adolescents (PRIYA) study: design and methods of a randomised
- controlled trial. BMC Nutr [Internet]. 2017 Dec [cited 2019 Jan 22];3(1). Available from:
- http://bmcnutr.biomedcentral.com/articles/10.1186/s40795-017-0143-5
- 514 27. Bayley N. Bayley Scales of Infant and Toddler Development: Bayley-III. Harcourt
- Assessment, Psych.Corporation; 2006.

- 516 28. Strand TA, Taneja S, Ueland PM, Refsum H, Bahl R, Schneede J, et al. Cobalamin and
- folate status predicts mental development scores in North Indian children 12-18 mo of
- age. Am J Clin Nutr. 2013 Feb;97(2):310–7.
- 519 29. Veena SR, Krishnaveni GV, Srinivasan K, Wills AK, Muthayya S, Kurpad AV, et al.
- Higher maternal plasma folate but not vitamin B-12 concentrations during pregnancy are
- associated with better cognitive function scores in 9- to 10- year-old children in South
- 522 India. J Nutr. 2010 May;140(5):1014–22.
- 523 30. Veena SR, Gale CR, Krishnaveni GV, Kehoe SH, Srinivasan K, Fall CH. Association
- between maternal nutritional status in pregnancy and offspring cognitive function during
- 525 childhood and adolescence; a systematic review. BMC Pregnancy Childbirth. 2016
- 526 Dec;16(1):220.
- 31. del Río Garcia C, Torres-Sánchez L, Chen J, Schnaas L, Hernández C, Osorio E, et al.
- Maternal MTHFR 677C>T genotype and dietary intake of folate and vitamin B<sub>12</sub>: their
- impact on child neurodevelopment. Nutr Neurosci. 2009 Feb;12(1):13–20.
- 32. Lai JS, Mohamad Ayob MN, Cai S, Quah PL, Gluckman PD, Shek LP, et al. Maternal
- plasma vitamin B12 concentrations during pregnancy and infant cognitive outcomes at 2
- years of age. Br J Nutr. 2019 Jun;121(11):1303–12.
- 33. Bonilla C, Lawlor DA, Ben-Shlomo Y, Ness AR, Gunnell D, Ring SM, et al. Maternal
- and offspring fasting glucose and type 2 diabetes-associated genetic variants and
- cognitive function at age 8: a Mendelian randomization study in the Avon Longitudinal
- Study of Parents and Children. BMC Med Genet. 2012 Sep 27;13:90.
- 537 34. Wu BTF, Dyer RA, King DJ, Richardson KJ, Innis SM. Early Second Trimester Maternal
- Plasma Choline and Betaine Are Related to Measures of Early Cognitive Development in
- Term Infants. Szecsi PB, editor. PLoS ONE. 2012 Aug 20;7(8):e43448.
- 35. Kvestad I, Taneja S, Kumar T, Hysing M, Refsum H, Yajnik CS, et al. Vitamin B12 and
- Folic Acid Improve Gross Motor and Problem-Solving Skills in Young North Indian
- Children: A Randomized Placebo-Controlled Trial. Cameron DW, editor. PLOS ONE.
- 543 2015 Jun 22;10(6):e0129915.
- 36. Bhat DS, Thuse NV, Lubree HG, Joglekar CV, Naik SS, Ramdas LV, et al. Increases in
- plasma holotranscobalamin can be used to assess vitamin B-12 absorption in individuals
- with low plasma vitamin B-12. J Nutr. 2009 Nov;139(11):2119–23.
- 37. Deshmukh US, Joglekar CV, Lubree HG, Ramdas LV, Bhat DS, Naik SS, et al. Effect of
- physiological doses of oral vitamin B12 on plasma homocysteine: a randomized, placebo-
- controlled, double-blind trial in India. Eur J Clin Nutr. 2010 May;64(5):495–502.
- 38. Yajnik CS, Behere RV, Bhat DS, Memane N, Raut D, Ladkat R, et al. A physiological
- dose of oral vitamin B-12 improves hematological, biochemical-metabolic indices and
- peripheral nerve function in B-12 deficient Indian adolescent women. Loor JJ, editor.
- PLOS ONE. 2019 Oct 10;14(10):e0223000.
- 39. Yajnik C, Kasture S, Kantikar V, Lubree H, Bhat D, Raut D, et al. Efficacy of B<sub>12</sub>
- Fortified Nutrient Bar and Yogurt in Improving Plasma B12 Concentrations—Results

From 2 Double-Blind Randomized Placebo Controlled Trials. Food Nutr Bull. 2021 Jun 30;037957212110254. 40. Devakumar D, Fall CHD, Sachdev HS, Margetts BM, Osmond C, Wells JCK, et al. Maternal antenatal multiple micronutrient supplementation for long-term health benefits in children: a systematic review and meta-analysis. BMC Med. 2016 Jun 16;14:90. 41. Green R, Allen LH, Bjørke-Monsen A-L, Brito A, Guéant J-L, Miller JW, et al. Vitamin B12 deficiency. Nat Rev Dis Primer. 2017 Dec 21;3(1):17040. 42. Fleming TP, Watkins AJ, Velazquez MA, Mathers JC, Prentice AM, Stephenson J, et al. Origins of lifetime health around the time of conception: causes and consequences. Lancet Lond Engl. 2018 May 5;391(10132):1842-52. 43. Amoako AA, Nafee TM, Ola B. Epigenetic Influences During the Periconception Period and Assisted Reproduction. In: Fazeli A, Holt WV, editors. Periconception in Physiology and Medicine [Internet]. Cham: Springer International Publishing; 2017 [cited 2021 Jul 14]. p. 15–39. (Advances in Experimental Medicine and Biology; vol. 1014). Available from: http://link.springer.com/10.1007/978-3-319-62414-3 2 44. Steegers-Theunissen RPM, Twigt J, Pestinger V, Sinclair KD. The periconceptional period, reproduction and long-term health of offspring: the importance of one-carbon metabolism. Hum Reprod Update. 2013 Nov 1;19(6):640-55. 

Table 1. Maternal characteristics at baseline and pregnancy, and child characteristics 591

Variables	n	Placebo Group	n	B12+MMN Group	n	B12 Group	p values	
Parental sociodemogr	aphic	characteristics						
Maternal age at 28 weeks gestation (years)	25	19.8 (1.0)	25	19.4 (1.1)	21	19.7 (1.1)	0.555	
Maternal education (years)	26	12.5 (11.0,13.0)	26	12.0 (10.0, 13.0)	21	12.0 (11.0, 13.5)	0.639	
Maternal height (cms)	25	158.2 (5.2)	25	158.7 (5.0)	21	157.8 (4.8)	0.852	
Maternal weight at 28 weeks gestation (kgs)	25	55.4 (48.6, 59.3)	25	51.2 (49.4, 54.4)	21	52.9 (47.0, 60.7)	0.656	
Maternal IQ	21	76.6 (9.5)	15	74.4 (8.8)	17	75.8 (7.2)	0.751	
Standard of Living	26	36.0 (30.5, 40.5)	26	38.0 (31.0, 40.0)	21	37.0 (32.0, 40.0)	0.923	
Index Paternal Education (years)	25	14.0 (10.5, 15.0)	24	12.0 (10.0, 15.0)	19	12.0 (10.0, 15.0)	0.656	
(Jeurs)		Maternal Micronuti	rients				p values (B12+MMN vs Placebo)	p values (B12 vs Placebo)
At screening							,	,
Vitamin B12 (pM)	27	151.0	26	159.5	21	138.0	0.350	0.860
Folate (nM)	27	(122.0, 193.0) 20.9 (15.3, 24.6)	26	(134.0, 219.0) 15.7 (11.3, 26.6)	21	(125.0, 190.0) 20.8 (15.3, 29.1)	0.357	0.698
Homocysteine (µmol/L) At 18 years	27	20.1 (15.1, 38.0)	26	18.6 (15.3, 30.3)	21	27.5 (17.0, 39.6)	0.646	0.434
Vitamin B12 (pM)	25	162.0 (125.9, 192.5)	26	285.0 (205.8, 368.7)	18	274.7 (224.7, 388.2)	<0.001***	<0.001***
Folate (nM)	26	23.0 (17.2, 29.8)	26	21.2 (15.3, 28.8)	18	20.4 (14.9, 28.3)	0.734	0.925
Homocysteine (µmol/L) At 28 weeks gestation	27	16.7 (11.7, 28.3)	26	9.60 (8.30, 13.4)	18	10.6 (9.22, 16.0)	<0.001***	0.013*
Hemoglobin (gm/dl)	25	10.4 (9.5, 11.0)	25	10.2 (9.4, 11.0)	21	10.4 (9.1, 10.7)	0.491	0.638
Vitamin B12 (pM)	25	134.0	25	164.0	21	204.0	0.007**	<0.001***
Holo-TC (pM)	25	(95.5, 163.0) 14.8 (8.85, 25.1)	25	(149.0, 218.5) 21.9 (15.3, 36.5)	21	(173.5, 261.0) 21.3 (16.9, 36.8)	0.027*	0.012*
Folate (nM)	25	47.9 (18.0, 71.5)	25	20.6 (10.2, 49.7)	21	28.5 (16.6, 51.4)	0.043*	0.302
Vitamin B2 (pM)	25	244.0 (210.5, 273.0)	25	276.0 (229.5, 304.5)	20	244.0 (221.7, 269.5)	0.028*	0.852
Viamin B6- pyridoxal-5-phospate (pM)	24	3.5 (2.3, 4.6)	25	4.6 (3.3, 7.4)	21	3.1 (2.6, 4.8)	0.117	0.357
Vitamin B6-pyridoxal (pM)	15	1.0 (0.8, 1.6)	12	1.1 (0.9, 1.3)	12	1.3 (1.0, 1.7)	0.786	0.922
Homocysteine (µmol/L)	25	7.0 (5.0, 9.2)	25	6.3 (4.3, 8.1)	21	5.1 (3.9, 7.2)	0.559	0.550

<b>Child Characteristics</b>								
Child age at assessment (months)	27	27 (26, 34)	26	29 (27, 36.2)	21	29 (26, 32)	0.623	0.901
Gender	27	Boys=18 (66.7%)	26	Boys=13 (50%)	21	Boys=11 (52.3%)		
Birth Anthropometry		,		,				
Gestation age (weeks)	27	39.0 (38.0, 40.2)	26	39.0 (38.0, 40.2)	21	39.4 (38.8, 40.2)	0.920	0.936
Birth weight (gm)	27	2908.6 (412.5)	26	2809.2 (458.6)	21	2788.9 (315.9)	0.411	0.277
Birth length (cm)	27	49.1 (46.8, 49.8)	26	48.2 (47.4, 49.8)	20	48.5 (47.2, 49.3)	0.990	0.328
Head circumference (cm) Cord Micronutrients	27	33.4 (1.0)	26	33.1 (1.0)	20	33.0 (0.9)	0.237	0.142
Cord Wheronathients								
Vitamin B12 (pM)	27	226.0 (138.0, 289.0)	26	275.5 (181.7, 313.7)	21	289.0 (167.0, 446.0)	0.240	0.200
Holo-TC (pM)	27	40.7 (23.3, 81.9)	26	79.4 (39.2, 125.0)	21	96.1 (39.4, 125.0)	0.021*	0.048*
Folate (nM)	27	55.9 (37.9, 70.8)	26	52.0 (36.8, 68.1)	21	42.7 (31.3, 80.0)	0.473	0.278
Vitamin B2 (pM)	26	357 (73.7)	25	316 (73.5)	20	314 (67.3)	0.053	0.924
Vitamin B6- pyridoxal-5-phospate (pM)	12	29.3 (18.6, 42.7)	13	25.0 (19.1, 39.5)	13	17.5 (11.6, 43.9)	0.494	0.298
Vitamin B6-pyridoxal (pM)	26	4.80 (3.6, 7.9)	25	5.70 (4.6, 8.3)	21	4.80 (3.2, 6.9)	0.187	0.806
Homocysteine (µmol/L)	27	8.30 (6.8, 11.6)	26	6.30 (4.8, 9.8)	21	6.60 (4.6, 11.9)	0.134	0.342
BDNF (pg/ml)	27	70.0 (31.0, 299.0)	26	106.0 (31.0, 412.2)	21	195.0 (31.0, 512.0)	0.620	0.364

Values represented as Mean (SD), Median (25th, 75th) or n (%) 

\*p<0.05, \*\*p<0.01 \*\*\*p<0.001 p-values calculated by t-test 

Holo-TC, holotranscobalamin; BDNF, Brain Derived Neurotrophic Factor 

Table 2. Comparison between placebo and supplemented groups on BSID-III domains

BSID-III domains	Placebo Group	B12+MMN Group	B12 Group	#p <b>v</b>	alue	\$p value		
				Group (B12+MMN vs Placebo)	Group (B12 vs Placebo)	Group (B12+MMN vs Placebo)	Group (B12 vs Placebo)	
Cognitive	90.0 (85.0, 95.0)	90.0 (85.0, 96.2)	95.0 (90.0, 100)	0.969	0.034*	0.781	0.044*	
Motor	94.0 (91.0, 100.0)	95.5 (90.2, 100.0)	97.0 (91.0, 107.0)	0.687	0.818	0.522	0.384	
Language	92.2 (7.8)	93.7 (9.87)	98.6 (10.1)	0.556	0.020*	0.633	0.020*	

Values represented as Mean (SD) or Median (25th, 75th) 607


\*p<0.05 608

606

#P value calculated by t test 609

\$P value calculated by ANCOVA; value adjusted for maternal baseline B12 levels 610

611 Language performance was normally distributed, and Mean (SD) are reported






Figure 1 Study timeline and consort